Skip to main content
Clinical Trials/CTRI/2017/09/009673
CTRI/2017/09/009673
Completed
Phase 4

Comparison of anti-platelet efficacy of four different marketed formulations of Aspirin in diabetic patients.

Dr Kanharam Patel0 sites121 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Patients with Type 2 DM receiving oral anti-diabetic and who have two or more risk factors for cardiovascular disease
Sponsor
Dr Kanharam Patel
Enrollment
121
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
August 24, 2016
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Kanharam Patel

Eligibility Criteria

Inclusion Criteria

  • Patients with Type 2 DM receiving oral anti\-diabetic with dietary modifications and who have two or more risk factors for cardiovascular disease.

Exclusion Criteria

  • Patients having age \<40 yrs.
  • Uncontrolled diabetes mellitus (Fasting BSL \> 300 mg/dL Despite therapy)
  • Uncontrolled Hypertension
  • Abnormal Liver Function Tests and/or Renal Function Tests.
  • Patients receiving any form or dose of Aspirin therapy for \>7 days
  • Patient receiving any other antithrombotic or anti\-coagulant therapy.
  • Patients having deranged bleeding and/ or clotting time at baseline study.
  • Patient on insulin.

Outcomes

Primary Outcomes

Not specified

Similar Trials